VEGFR2 heterogeneity and response to anti-angiogenic low dose metronomic cyclophosphamide treatment
Steven G. Patten(University of Guelph), Brenda L. Coomber(University of Guelph)
Cited by 33
Related Papers
Molecular blockade of VEGFR2 in human epithelial ovarian carcinoma cells
|Laboratory Investigation|2010|30
Modulation of the Tumor Suppressor Protein α-Catenin by Ischemic Microenvironment
|American Journal Of Pathology|2009|8
Lack of Efficacy of Combined Antiangiogenic Therapies in Xenografted Human Melanoma
|Journal of Oncology|2011|0